CD274 and non-small cell lung carcinoma: KEYNOTE clinical trials have demonstrated efficacy for pembrolizumab as first-line monotherapy in treating NSCLC with increased PD-L1 expression (KEYNOTE-024 and KEYNOTE-042), as well as second-line monotherapy with PD-L1 expression (KEYNOTE-010) [43].